Review
doi: 10.2174/1381612033455251.
Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography
Affiliations
- PMID: 12678876
- DOI: 10.2174/1381612033455251
Item in Clipboard
Review
Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography
Curr Pharm Des.
2003.
Abstract
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16alpha-[(18)F]fluoro-17beta-oestradiol (FES) pathways involved in metabolism with [(18)F]fluorodeoxy-glucose ([(18)F]FDG), (11)C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[(11)C]thymidine, cell death using [(124)I]annexin V, [(124)C]colchicine for drug resistance and angiogenesis using [(124)I]anti-VEGF.
Similar articles
-
Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.Curr Pharm Des. 2001 Dec;7(18):1863-92. doi: 10.2174/1381612013396907. Curr Pharm Des. 2001. PMID: 11772355 Review.
-
Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance.Curr Pharm Des. 2008;14(28):2914-31. doi: 10.2174/138161208786404344. Curr Pharm Des. 2008. PMID: 18991710 Review.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Positron emission tomography imaging of cell proliferation in oncology.Clin Oncol (R Coll Radiol). 2004 May;16(3):176-85. doi: 10.1016/j.clon.2003.10.009. Clin Oncol (R Coll Radiol). 2004. PMID: 15191004 Review.
-
PET for in vivo pharmacokinetic and pharmacodynamic measurements.Eur J Cancer. 2002 Nov;38(16):2094-107. doi: 10.1016/s0959-8049(02)00413-6. Eur J Cancer. 2002. PMID: 12387835 Review.
Cited by
-
Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data.J Pharmacokinet Pharmacodyn. 2006 Feb;33(1):75-91. doi: 10.1007/s10928-005-9001-1. J Pharmacokinet Pharmacodyn. 2006. PMID: 16402287
-
The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):257-63. doi: 10.1007/s00259-004-1611-0. Epub 2004 Sep 4. Eur J Nucl Med Mol Imaging. 2005. PMID: 15791434
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
